KR20190012593A - Gellan-gum hydrogels composition containing hesperidin - Google Patents

Gellan-gum hydrogels composition containing hesperidin Download PDF

Info

Publication number
KR20190012593A
KR20190012593A KR1020170095823A KR20170095823A KR20190012593A KR 20190012593 A KR20190012593 A KR 20190012593A KR 1020170095823 A KR1020170095823 A KR 1020170095823A KR 20170095823 A KR20170095823 A KR 20170095823A KR 20190012593 A KR20190012593 A KR 20190012593A
Authority
KR
South Korea
Prior art keywords
cartilage
hesperidin
composition
gellan gum
hydrogel
Prior art date
Application number
KR1020170095823A
Other languages
Korean (ko)
Other versions
KR102008232B1 (en
Inventor
강길선
전성현
송정은
이기원
조훈휘
Original Assignee
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교산학협력단 filed Critical 전북대학교산학협력단
Priority to KR1020170095823A priority Critical patent/KR102008232B1/en
Publication of KR20190012593A publication Critical patent/KR20190012593A/en
Application granted granted Critical
Publication of KR102008232B1 publication Critical patent/KR102008232B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/18Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • Y10S514/825

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is characterized by being used as a composition for treating cartilage damage by using an injectable hydrogel composition having a gellan-gum hydrogel, which is a biologically suitable natural material, as a base, and hesperidin is mixed therein. When the composition for treating cartilage damage of the present invention is injected into a body, it is possible to have an effect of hesperidin which alleviates inflammation by collagen production and anti-inflammatory action, and thus have high elasticity and durability unique to gellan gum, thereby being suitable as an injection for cartilage treatment. In addition, the composition for treating cartilage damage has no cytotoxicity, has an advantage of not being dissolved by inflammatory reaction or toxic substances, and thus, can minimize disadvantages which occur from an existing autologous chondrocyte implantation by collecting an autologous knee cartilage in order to enhance a cartilage regeneration effect.

Description

헤스페리딘이 함유된 젤란검 하이드로겔 조성물 {Gellan-gum hydrogels composition containing hesperidin} Gellan-gum hydrogels composition containing hesperidin < RTI ID = 0.0 >

본 발명은 헤스페리딘이 함유된 젤란검 하이드로겔 조성물에 관한 것으로서, 더욱 상세하게는 손상된 연골복구와 골관절염 치료를 위한 생체 적합하고 주입 가능한 헤스페리딘이 첨가된 젤란검을 지지체로 이용하여 하이드로겔 형태로 구성되는 조성물과 이를 연골재생 및 골염증 완화 효과를 갖는 연골재생용 조성물에 적용하여 주입하는 발명에 관한 것이다.The present invention relates to a gelatin gum hydrogel composition containing hesperidin, and more particularly, to a gelatin gum hydrogel composition comprising hesperidin in the form of hydrogels using gellan gum supplemented with biocompatible and injectable hesperidin for the repair of damaged cartilage and osteoarthritis And a method of injecting the same into a composition for cartilage regeneration having cartilage regeneration and bone inflammation relieving effects.

퇴행성 관절 질병인 골관절염은 연골 퇴보와 뼈 과성장의 특성을 나타낸다. 골관절염은 임상실습에서 보이는 가장 흔한 퇴행성 골절과 노인 장애의 주된 요인이다. 연골은 연골세포와 연골조직으로 구성된 조직으로 충격을 흡수하여 관절을 보호하는 완충작용을 하고 관절면을 뒤덮는 초자 연골의 관절 연골인 윤활액이 들어있는 관절 주머니를 가지는 윤활 관절은 뼈 사이의 마찰력을 줄여 움직임을 부드럽게 한다. Osteoarthritis, a degenerative joint disease, is characterized by cartilage degeneration and bone hyperplasia. Osteoarthritis is the most common degenerative fracture and elderly disorder seen in clinical practice. The cartilage is a tissue composed of cartilage cells and cartilage tissue. It absorbs shock to protect the joints. The cartilage of the cartilage of the cartilage of the suprasellar cartilage covers the joint surface. Smooth movement.

이러한 관절을 보호하는 역할을 하고 있는 연골이 노화와 비만, 무리한 관절사용으로 마모되거나 퇴행성 변화로 인해 파열되면 골관절염 질병의 원인이 된다. 골관절염은 관절 염증, 통증, 부기, 부종, 변형 등의 증상들이 나타나는데 이러한 골관절염 증상들은 환자 삶의 질을 저하시킨다. 하지만, 관절 연골의 낮은 자가치료 능력 때문에 골관절염은 현재로써는 정확한 치료방법이 없어, 도전적인 질병 분야이다. [Bone Res (Wei Zhang, Hongwei Ouyang, Crispin R Dass, and Jiake Xu) 2016; 4; 15040.] The cartilage that protects these joints is worn out due to aging, obesity, excessive use of joints, or rupture due to degenerative changes, which causes osteoarthritis. Osteoarthritis can manifest symptoms such as joint inflammation, pain, swelling, edema, and deformity. These symptoms of osteoarthritis reduce the quality of life in patients. However, due to the low self-healing ability of articular cartilage, osteoarthritis is now a challenging disease area because there is no correct treatment. [Bone Res (Wei Zhang, Hongwei Ouyang, Crispin R Dass, and Jiake Xu) 2016; 4; 15040.]

궁극적으로 골관절염의 치료는 환자의 통증을 줄이고 관절의 기능을 개선시키는데 목적이 있다. 하지만, 기존의 비스테로이드성 소염제인 진통해열제와 합성 진통 마취제들은 통증과 부종을 완화 시키는 데는 효율적이지만 근본적인 문제인 연골의 손상을 막을 수 없고 장기적인 복용이 힘들며, 대부분 심각한 부작용을 동반한다. Ultimately, the treatment of osteoarthritis is aimed at reducing patient pain and improving joint function. However, existing non-steroidal anti-inflammatory agents, analgesic antipyretics and synthetic analgesic anesthetics, are effective at alleviating pain and edema, but they can not prevent cartilage damage, which is a fundamental problem, and are difficult to take long-term, with most serious side effects.

따라서 연골 재생을 증진시키고 손상된 연골 복구의 치료법으로 최근 조직 재생과 치료의 효율성이 증대함에 따라 연골 재생에 대한 조직공학적 방법의 필요성이 제기되어 왔다.Thus, as a result of improving the efficiency of tissue regeneration and treatment by improving cartilage regeneration and repairing damaged cartilage repair, there has been a need for a tissue engineering method for cartilage regeneration.

젤란검(Gellan Gum)은 생분해성 물질로 생체 주입에 적합하고 내열성, 내산성, 내효소성의 우수한 물성뿐만 아니라 친수콜로이드(hydrocolloid)로써 신체에 주입시 겔을 형성하여 손상된 부위를 촉촉하게 유지하고, 괴사조직의 자연분해를 도와 생체조직공학에서의 응용이 광범위하다. 젤란검은 O-글리코시드(O-glycosidically)가 결합된 에스터(ester)로써 아실기(Acyl group)를 함유하고 있으며, 아실기의 함유량에 따라 하이아실젤란검(high acyl gellan gum), 로우아실젤란검(low acyl gellan gum)으로 나누어진다. 특히, 젤란검의 구성성분인 글루코산은 실제 연골의 글리코사민글리칸과 유사한 환경조성을 하는 것으로 알려져 연골 복구재생 연구에 적합하다.(Balakrishnan B1, Joshi N1, Jayakrishnan A2, Banerjee R3, Self-crosslinked oxidized alginate/gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration, Acta Biomater, 2014 Aug;10(8):3650-63.) Gellan Gum is a biodegradable material that is suitable for bioinjection and has excellent properties of heat resistance, acid resistance and resistance to enzymes as well as hydrophilic colloid (hydrocolloid) to form a gel when injected into the body to keep the injured area moist, The application in biomedical engineering is wide to help natural decomposition of tissue. It is an ester with an O-glycosidic bond and contains an acyl group. Depending on the content of the acyl group, a high acyl gellan gum, a low acyl gellan gum, It is divided into gum (low acyl gellan gum). In particular, glucan, which is a component of gellan gum, is known to have an environment similar to that of the actual cartilage glycosaminoglycan, making it suitable for studies of cartilage restoration and regeneration (Balakrishnan B1, Joshi N1, Jayakrishnan A2, Banerjee R3, Self-crosslinked oxidized alginate / gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration, Acta Biomater, 2014 Aug; 10 (8): 3650-63.)

또한, 헤스페리딘(Hesperidin)은 비타민 P의 일종으로 콜라겐 생성을 돕고 항염증 작용, 노화에 관련된 질병에 효과가 있으며, 관절 및 연골에 영향을 준다고 알려져 있다 (일본등록특허 제4838772호, 일본공개특허 제2005-255527호). Hesperidin is a kind of vitamin P, which is known to help collagen production, to be effective in anti-inflammatory and aging-related diseases, and to affect joints and cartilage (Japanese Patent No. 4838772, 2005-255527).

상기 언급한 조직공학적 생체재료를 이용한 주입형 하이드로겔은 그 필요성에도 불구하고, 연구가 전무한 실정이다.Despite the necessity of injection-type hydrogels using the above-mentioned tissue engineering biomaterials, research has not been conducted.

일본등록특허 제4838772호Japanese Patent No. 4838772 일본공개특허 제2005-255527호Japanese Patent Application Laid-Open No. 2005-255527

1. Balakrishnan B1, Joshi N1, Jayakrishnan A2, Banerjee R3, Self-crosslinked oxidized alginate/gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration, Acta Biomater, 2014 Aug;10(8):3650-63.1. Balakrishnan B1, Joshi N1, Jayakrishnan A2, Banerjee R3, Self-crosslinked oxidized alginate / gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration, Acta Biomater, 2014 Aug; 10 (8): 3650-63.

상기와 같은 종래기술의 문제점을 개선하기 위하여, 헤스페린과 젤란검을 활용하여 연골 손상을 효율적으로 개선하고 골관절염을 치료할 수 있도록 하기 위한 방안의 개발을 해결과제로 한다.In order to solve the problems of the prior art as described above, development of a method for efficiently improving cartilage damage and treating osteoarthritis using hesperin and gellan gum is a problem to be solved.

그러므로 본 발명자들은 수술부위를 최소화할 수 있는 비외과적(Non-surgical)인 조직공학적 방법을 통해, 연골 재생 및 골 관절염 치료를 위한 방법을 개발하고자 하였다. 그 결과, 연골치료를 위한 헤스페리딘이 배합된 젤란검 하이드로겔 주입식 관절염 치료제를 개발하여, 연골 복구를 확인함으로써 본 발명을 완성하였다. The present inventors therefore sought to develop a method for cartilage regeneration and osteoarthritis treatment through a non-surgical, tissue engineering method capable of minimizing the surgical site. As a result, the inventors of the present invention completed the present invention by developing gellan gum hydrogel-injected arthritis treating agent containing hesperidin for treating cartilage and confirming cartilage repair.

따라서 본 발명의 목적은 수술부위를 최소화할 수 있는 비외과적인 조직공학적 방법을 통해, 연골 재생 및 골관절염 치료를 위한 하이드로겔 조성물을 제공하는 데 있다.Accordingly, an object of the present invention is to provide a hydrogel composition for cartilage regeneration and osteoarthritis treatment through a non-surgical tissue engineering method capable of minimizing a surgical site.

또한, 본 발명의 다른 목적은 연골치료를 위한 헤스페리딘이 배합된 젤란검 하이드로겔로서 주입식으로 사용하여 관절염 치료와 연골 복구가 가능한 연골 재생 및 손상 치료용 조성물을 제공하는 데 있다.Another object of the present invention is to provide a composition for treatment of cartilage regeneration and injury, which is capable of treating arthritis and restoring cartilage by using gellan gum hydrogel containing injected hesperidin for cartilage treatment.

또한, 본 발명의 또 다른 목적은 연골 결함과 관절염 치료를 위해 항염증, 항산화, 연골 재생효과가 있는 헤스페리딘과 젤란검을 함유한 연골 치료용 주사제 조성물을 제공하는 데 있다. Another object of the present invention is to provide an injectable composition for treating cartilage containing hesperidin and gellan gum which has anti-inflammatory, antioxidant and cartilage regeneration effects for treating cartilage defects and arthritis.

위와 같은 본 발명의 과제 해결을 위하여, 본 발명은 연골 재생 및 골염증을 완화 유효성분으로 헤스페리딘이 젤란검에 배합되어 하이드로겔 형태로 이루어진 것을 특징으로 하는 헤스페리딘이 함유된 젤란검 하이드로겔 조성물을 제공한다.In order to solve the above-mentioned problems, the present invention provides a gellan gum hydrogel composition containing hesperidin, characterized in that hesperidin is mixed with gellan gum as an effective ingredient for alleviating cartilage regeneration and bone inflammation, and is formed into a hydrogel form do.

또한, 본 발명은 헤스페리딘이 함유된 젤란검 하이드로겔 조성물을 연골재생 유효성분으로 포함하는 연골 손상 치료용 조성물을 제공한다.The present invention also provides a composition for treating cartilage damage comprising a gellan gum hydrogel composition containing hesperidin as a cartilage regeneration effective ingredient.

또한, 본 발명은 헤스페리딘과 젤란검을 함유한 상기 연골 손상 치료용 조성물을 포함하는 주입식 관절염 치료제를 제공한다.In addition, the present invention provides a therapeutic agent for an injectable arthritis comprising the composition for treating cartilage damage containing hesperidin and gellan gum.

본 발명의 특징 및 이점을 요약하면 다음과 같다.The features and advantages of the present invention are summarized as follows.

(i) 본 발명은 생체 재료를 이용하여 연골 복구 및 골 관절염 치료제로서 헤스페리딘(Hesperidin)과 젤란검(Gellan-gum)을 포함하는 연골 재생 및 관절염 치료용 조성물을 제공함으로써 생체공학적 관절염 치료에 매우 유용하다.(i) The present invention provides a composition for treating cartilage regeneration and arthritis, which comprises hesperidin and gellan-gum as cartilage restoration and osteoarthritis treatment agents using biomaterials, and is very useful for treatment of bioengineered arthritis Do.

(ii) 본 발명에 따른 연골재생용 조성물은 헤스페리딘이 배합된 연골 손상 치료용 젤란검 하이드로겔 형태의 연골 재생용 조성물을 이용하여 통해 연골 손상의 치료 효과를 크게 개선할 수 있으며, 간편하게 주입식으로 손상 부위에 직접 적용할 수 있는 효과가 있다. (ii) The composition for regenerating cartilage according to the present invention can greatly improve the therapeutic effect of cartilage damage through use of gellan gum hydrogel-type composition for regenerating cartilage damaged with hesperidin, It has an effect that can be directly applied to the site.

(iii) 본 발명은 연골재생용 조성물을 조직공학적 주입형 하이드로겔 형태로 제작함으로써, 비외과적인 치료로 인해 수술에 따른 부작용 및 수술 시간을 크게 단축할 수 있는 효과가 있다. (iii) According to the present invention, since the composition for regeneration of cartilage is made into a tissue engineering injection type hydrogel, the side effects and the operation time can be greatly shortened due to the non-surgical treatment.

도 1은 젤란검 하이드로겔에 헤스페리딘이 함량별 (0 mg, 1 mg, 2 mg, 4 mg) 로 첨가된 본 발명의 헤스페리딘과 젤란검을 함유한 연골재생용 조성물을 지지체 형태로 제작한 것을 보여주는 사진이다.
도 2는 본 발명에 따라 제조된 헤스페리딘/젤란검 하이드로겔 지지체에 파종된 토끼 연골세포의 증식률을 확인한 그래프이다.
도 3은 본 발명에 따라 제조된 헤스페리딘/젤란검 하이드로겔 지지체를 동결건조 시킨 다음 지지체 표면과 그 위에 파종된 토끼 연골세포를 파종 후 2주 뒤에 BIo-LV SEM을 통해 확인한 사진이다.
도 4는 본 발명에 따라 제조된 헤스페리딘/젤란검 하이드로겔 지지체의 압축강도를 측정한 그래프이다.
도 5a. 5b, 5c는 본 발명에 따른 헤스페리딘/젤란검 하이드로겔 지지체에서 헤스페리딘 함량을 달리한 헤스파리딘 함량별 젤란검 하이드로겔 지지체에 파종된 토끼연골세포의 연골 관련 마커 유전자 발현도를 항존유전자(Housekeeping gene) Beta-actin을 사용하여 RT-PCR로 측정한 그래프이다.
FIG. 1 is a photograph showing the preparation of a composition for cartilage regeneration containing hesperidin and gellan gum of the present invention in which gelatin gum hydrogel was added with the amounts of hesperidin (0 mg, 1 mg, 2 mg, and 4 mg) to be.
FIG. 2 is a graph showing the proliferation rate of rabbit chondrocytes sown on the hesperidin / gellan gum hydrogel support prepared according to the present invention.
FIG. 3 is a photograph of the surface of the support and the rabbit chondrocytes sown on the leaf after freeze-drying the hesperidin / gellan gum hydrogel support prepared according to the present invention through BIo-LV SEM 2 weeks after sowing.
4 is a graph showing compressive strength of a hesperidin / gellan gum hydrogel support prepared according to the present invention.
5a. 5b and 5c show the expression of the cartilage-related marker gene in the rabbit chondrocytes seeded on the gellan gum hydrogel support by the content of hesperidin in different amounts of hesperidin in the hesperidin / gellan gum hydrogel support according to the present invention, Beta-actin as a control.

이하, 본 발명을 하나의 구현예로서 더욱 상세하게 설명하면 다음과 같다.Hereinafter, the present invention will be described in more detail as an embodiment.

본 발명의 일 양태에 따르면, 본 발명은 관절염 등 연골 손상의 치료를 위하여, 생체 적합한 고분자인 헤스페리딘이 배합된 젤란검 하이드로겔 조성물을 제공한다. According to one aspect of the present invention, there is provided a gellan gum hydrogel composition comprising a biocompatible polymer, hesperidin, for the treatment of cartilage damage such as arthritis.

본 발명의 바람직한 구현예에 따르면 기존의 연골치료 수술법과는 달리, 추가적 수술과 부작용을 최소화하는 방법의 치료를 위한 새로운 조성물로서, 연골 세포의 증식과 기능유지에 효과적인 조직공학적 생체 적합 재료를 이용하여, 연골 손상부분을 효과적으로 재생시킬 수 있는 새로운 구성의 주입식 적용이 가능한 젤란검 하이드로겔을 조성물을 제조하였다.According to a preferred embodiment of the present invention, unlike the conventional cartilage treatment method, a new composition for treatment of a method for minimizing additional surgery and side effects is provided, which uses a tissue-engineered biocompatible material effective for proliferation and function maintenance of cartilage cells , A novel composition of injectable gellan gum hydrogel which can effectively regenerate cartilage damaged parts was prepared.

본 발명의 바람직한 구현예에 따르면, 본 발명에서 사용되는 헤스페리딘 (Hesperidin)은 생체이용에 적합하고 콜라겐 생성을 돕고 항염증 작용을 하여 노화에 관련된 질병에 효과가 있으며 관절 연골에 긍정적인 영향을 준다고 알려져 있다. According to a preferred embodiment of the present invention, it is known that hesperidin used in the present invention is suitable for bioavailability, assists in collagen production, has an anti-inflammatory action, is effective for diseases related to aging, and positively affects articular cartilage have.

본 발명에서 사용되는 젤란검 하이드로겔은 생체에 적합한 천연 재료로서, 높은 탄성률과 제조시 조절 가능한 강성을 가지고 있다. 젤란검 하이드로겔은 온도가 특정온도 이하로 내려가면 2차 코일 헬릭스 구조를 이루어 겔화 된다. 특히, 젤란검은 낮은 독성을 가질 뿐만 아니라 다루기가 쉽기 때문에, 헤스페리딘과 혼합하여 하이드로겔을 제조하면, 외과적 수술을 하지 않고 주입식 치료제로 사용할 수 있다. The gellan gum hydrogel used in the present invention is a natural material suitable for a living body, and has a high elastic modulus and a rigidity that can be controlled during production. The gellan gum hydrogel has a secondary coiled helix structure that gels when the temperature falls below a certain temperature. In particular, since gellan black has low toxicity and is easy to handle, when hydrogels are mixed with hesperidin, they can be used as an injectable remedy without surgical operation.

본 발명의 바람직한 구현예에 따르면, 젤란검 하이드로겔의 농도는 0.5~ 1중량%, 더욱 좋기로는 0.7-1중량%인 것이 바람직하다. 즉, 본 발명에서 사용하는 젤란검 하이드로겔은 순수 젤란검에 헤스페리딘을 혼합하고 배합한 하이드로겔로 구성된 것으로서, 예컨대 헤스페리딘를 첨가한 후 가교하여 바이옵시 펀치를 사용하게 되면 원통형 형태의 하이드로겔 조성물로 구성될 수 있다.According to a preferred embodiment of the present invention, the concentration of the gellan gum hydrogel is preferably 0.5 to 1% by weight, more preferably 0.7 to 1% by weight. That is, the gellan gum hydrogel used in the present invention is composed of pure gellan gum and a hydrogel in which hesperidin is blended and blended. When a bi-os punch is used after cross-linking after adding hesperidin, for example, it is composed of a cylindrical hydrogel composition .

본 발명의 바람직한 구현예에 따르면, 헤스페리딘의 농도는 젤란검에 대해 5 ~ 20중량% 인 것이 바람직하다. 만일, 그 함량이 너무 낮으면 첨가 효과가 없고, 너무 높으면 세포 과성장에 따른 비대 및 세포사멸이 이루어져 바람직하지 않은 문제가 발생할 수 있다.According to a preferred embodiment of the present invention, the concentration of hesperidin is preferably 5 to 20% by weight based on gellan gum. If the content is too low, there is no addition effect, and if it is too high, hypertrophy and cell death due to cell growth may occur, which may cause undesirable problems.

본 발명의 바람직한 구현예에 따르면, 본 발명의 하이드로겔 조성물은 예컨대 무릎 연골 손상부위에 적용하는 경우 주사제를 이용하여 곧바로 주입 가능한 제형일 수 있다. 그러므로 본 발명의 하이드겔 형태의 연골 손상 치료용 조성물은 그 사용이 기존에 비해 현저하게 편리한 효과가 있다.According to a preferred embodiment of the present invention, the hydrogel composition of the present invention may be a ready-to-inject dosage form, for example, when injected into a knee cartilage damage site. Therefore, the composition for treating cartilage damage in the hydrogel form of the present invention has remarkably convenient effect in use compared to the conventional one.

그러므로 본 발명은 상기와 같은 헤스페리딘이 함유된 젤란검 하이드로겔 조성물을 유효성분으로 포함하는 연골 손상 치료용 조성물을 제공한다.Therefore, the present invention provides a composition for treating cartilage damage comprising the above-described gelatin gum hydrogel composition containing hesperidin as an active ingredient.

본 발명의 연골 손상 치료용 조성물을 체내에 주입하면 콜라겐 생성을 돕고 항염 작용으로 염증 완화에 도움을 주는 헤스페리딘의 효과와 더불어 젤란검 특유의 높은 탄성과 내구성으로 인하여 연골치료용 주사제로써 적합하다. The composition for treating cartilage damage according to the present invention is injected into the body to be effective as an injection for cartilage treatment because of its high elasticity and durability unique to gellan gum as well as the effect of hesperidin which helps collagen production and anti-inflammatory action to relieve inflammation.

또한, 본 발명에 따른 조성물은 세포 독성이 없고, 염증 반응이나 독성 물질에 의해 녹지 않는 장점이 있다. In addition, the composition according to the present invention has no cytotoxicity and has an advantage of being insoluble due to inflammatory reaction or toxic substances.

본 발명에 따르면, 본 발명의 연골 손상 치료용 조성물을 사용하는 경우 기존에 연골 재생 효과를 증진시키기 위해, 예컨대 자가 무릎연골을 채취하여, 자가 연골세포 이식술에서 생기는 방법으로 치료하던 방법에서 나타나는 여러 가지 단점을 최소화할 수 있는 것이다.According to the present invention, when the composition for treating cartilage damage according to the present invention is used, it is possible to improve the cartilage regeneration effect, for example, by collecting the autologous knee cartilage and treating various methods The disadvantages can be minimized.

또한, 본 발명에 따르면 상기와 같은 연골 손상 치료용 조성물에는 추가적으로 히알루론산 (hyaluronic acid), TGF-β1 중에서 선택된 하나 이상이 통상의 방법으로 혼합 사용될 수 있다.In addition, according to the present invention, at least one selected from hyaluronic acid and TGF-? 1 may be added to the composition for treating cartilage damage as described above in a conventional manner.

또한, 본 발명은 상기와 같은 연골 손상 치료용 조성물은 주사에 적당한 기계적 강도를 가짐으로써 주입 가능한 주사용 관절염 치료제로 제공될 수 있다. 즉, 본 발명에 따른 하이드로겔 조성물은 연골 손상 부위에 주사하는 경우 예컨대, 1mg 헤스페리딘/ 1% 젤란검 농도의 주사제로 적용 가능하며, 이 경우 대체로 14일 내지 21일 경과 후에는 연골 재생 효과가 나타나 연골 손상부위에 대한 치료효과가 이루어지기 때문에 손상된 용이하게 연골을 치료할 수 있게 되는 것이다.In addition, the composition for treating cartilage damage as described above can be provided as an injectable therapeutic agent for injectable arthritis by having an appropriate mechanical strength for injection. In other words, the hydrogel composition according to the present invention can be applied as an injectable drug with a concentration of 1 mg of hesperidin / 1% gellan gum when injected into a cartilage damaged area. In this case, the cartilage regenerating effect is generally observed after 14 to 21 days Since the therapeutic effect on the cartilage damage site is made, the cartilage can be easily damaged and damaged.

본 발명은 상기와 같은 연골 손상 치료용 조성물을 포함하는 주사용 관절염 치료제를 포함한다.The present invention includes a therapeutic agent for injectable arthritis comprising the composition for treating cartilage damage as described above.

본 발명의 바람직한 구현예에 따르면, 본 발명의 연골 손상 치료용 조성물은 주사형태로 주입하는 경우 연골손상 부위에 따라 3-5ml 의 범위 내에서 그 투여량을 조절할 수 있다. 바람직하게는 체중 60Kg 중량의 성인 기준으로 무릎 관절염 환자에 대해 1회 3-5ml의 범위 내에서 투여하는 것이 바람직하다.According to a preferred embodiment of the present invention, the composition for treating cartilage damage according to the present invention can control its dose within a range of 3-5 ml according to a cartilage damage site when injected in an injection form. Preferably, it is administered within the range of 3-5 ml once per osteoarthritis patient on an adult basis, preferably 60 kg body weight.

본 발명의 바람직한 구현예에 따르면, 본 발명의 연골 손상 투여용 조성물은 연골 손상 정도 및 재생 정도에 따라 주 또는 월 단위로, 반복 투여가 가능하다.According to a preferred embodiment of the present invention, the composition for administration of cartilage damage according to the present invention can be repeatedly administered on a weekly or monthly basis depending on the degree of cartilage damage and the degree of regeneration.

본 발명의 연골 손상 치료용 조성물을 체내에 주입하면 관절 조직 보호와, 항산화 효과 및 세균감염을 억제하고 높은 탄성과 내구성으로 인하여 주입식으로 사용하여 연골 손상 치료제로 유용하게 적용될 수 있다.When the composition for treating cartilage damage of the present invention is injected into the body, it can be effectively used as a therapeutic agent for cartilage damage, because it protects the joint tissue, inhibits antioxidative effect and bacterial infection, and is used as an injection type because of high elasticity and durability.

특히, 연골 재생 효과를 증진시키기 위해, 자가 무릎 연골을 채취하여, 기존 자가 연골세포 이식술에서 생기는 단점을 최소화할 수 있다.In particular, in order to improve the cartilage regeneration effect, the self-knee cartilage can be collected to minimize the disadvantages of existing autologous chondrocyte implantation.

이하, 본 발명을 실시예에 의해 자세히 설명한다. 하기에 나오는 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. The following examples serve to illustrate the present invention and are not intended to limit the scope of the present invention.

비교예 및 실시예 1 - 3 : 헤스페리딘/젤란검 하이드로겔 조성물의 제조Comparative Example and Example 1-3: Preparation of a Hesperidin / Gellan gum Hydrogel Composition

지용성 물질인 헤스페리딘의 용해는 EtOH를 이용한다. 중탕시킨 90℃의 3차 증류수(100 ml)에 젤란검(0.7g)(Sigma)을 용해시켜, 0.7 % 젤란검 수용액을 20분간 교반시키며 가열한다. 젤란검 파우더가 완전히 녹으면 0.03 % 염화칼슘(0.03g)을 넣고 10분간 용해시킨다. The dissolution of the lipid-soluble material hesperidin is carried out using EtOH. Gellan gum (0.7 g) (Sigma) was dissolved in distilled water (100 ml) of tertiary water at 90 ° C, and the aqueous 0.7% gellan gum solution was stirred and heated for 20 minutes. When the gellan gum powder is completely dissolved, add 0.03% calcium chloride (0.03 g) and dissolve for 10 minutes.

시켜 준비한다. 60℃ 까지 온도가 낮아진 젤란검 수용액에 각각 0(비교예), 1mg(실시예 1), 2mg(실시예 2) 및 4mg(실시예 3) 함량의 헤스페리딘 수용액을 넣는다. 젤란검 수용액과 헤스페리딘 수용액을 섞은 후 페트리 디쉬에 붓고 상온에서 굳혀서 하이드로겔 조성물을 얻었다.. (Comparative Example), 1 mg (Example 1), 2 mg (Example 2) and 4 mg (Example 3) of aqueous solution of hesperidin are added to the gellan gum aqueous solution whose temperature is lowered to 60 캜. The gellan gum aqueous solution and the hesperidin aqueous solution were mixed, poured into Petri dishes, and hardened at room temperature to obtain a hydrogel composition.

이렇게 얻은 하이드로겔은 굳은 겔 형태이므로 이를 바이옥시 펀지를 이용해 직경 6 mm, 높이 5 mm 로 잘라서 그 제품 사진을 도 1에 제시하였다.The hydrogel thus obtained is in the form of a hard gel, and is cut into a diameter of 6 mm and a height of 5 mm using a bioxy punch, and a photograph of the product is shown in FIG.

도 1은 젤란검 하이드로겔에 헤스페리딘이 함량별 (0 mg, 1 mg, 2 mg, 4 mg) 로 첨가된 본 발명의 헤스페리딘과 젤란검을 함유한 연골재생용 조성물을 지지체 형태로 제작한 것을 보여주는 사진이다. FIG. 1 is a photograph showing the preparation of a composition for cartilage regeneration containing hesperidin and gellan gum of the present invention in which gelatin gum hydrogel was added with the amounts of hesperidin (0 mg, 1 mg, 2 mg, and 4 mg) to be.

실험예 : Experimental Example:

(1) 무릎 연골세포의 채취 및 배양(1) Collection and culture of knee cartilage cells

연골 세포를 얻기 위해 생후 2주된 암컷 뉴질랜드 화이트 토끼(Hanil laboratory animal center, Wanju, Korea)를 사용하였다. 토끼의 무릎 관절 사이에서 연골부위를 절개한 후 PBS(pH 7.4, Gibco, NY, USA)로 여러 번 세척 한 다음 연골세포를 긁어내었다. 긁어낸 연골세포는 코니컬 튜브에 넣고 1200 rpm, 4℃에서 3분 동안 2번 원심분리 하였다. To obtain chondrocytes, 2-week-old female New Zealand white rabbits (Hanil laboratory animal center, Wanju, Korea) were used. The cartilage was cut between the knee joints of rabbits and then washed several times with PBS (pH 7.4, Gibco, NY, USA), and the chondrocytes were scraped off. The scraped chondrocytes were placed in a conical tube and centrifuged twice at 1200 rpm, 4 ° C for 3 minutes.

원심분리가 끝난 연골세포에 Dulbecco’s modified eagle medium(DMEM/F-12, Gibco), 10% 우태아 혈청(FBS, Gibco), 그리고 1% 항생제(100 units/mL 페니실린과 100μg/mL 스트렙토마이신)를 혼합한 배양액 10 mL와 0.2 wt% 콜라게네이즈 A형(Roche, Indianapolis, USA) 200μL를 첨가하여 36℃, 5% CO2조건하의 인큐베이터 안에서 1일 동안 콜라겐을 분해하였다. 1일 후 1200 rpm, 4℃에서 3분 동안 원심분리 후 피펫팅하여 세포 배양접시(Cell culture dish)에 배양액과 함께 분주하였으며, 3일에 한번 씩 배양액을 교체해주었다. 파종에 사용된 세포는 Passage 2의 세포를 지지체당 1×105cell/scaffold로 하였다.Dulbecco's modified eagle medium (DMEM / F-12, Gibco), 10% fetal bovine serum (FBS, Gibco) and 1% antibiotic (100 units / mL penicillin and 100 μg / mL streptomycin) were added to the centrifuged chondrocytes 10 mL of the mixed culture and 200 μL of 0.2 wt% collagenase type A (Roche, Indianapolis, USA) were added and the collagen was degraded in an incubator at 36 ° C and 5% CO 2 for 1 day. After 1 day, the cells were centrifuged at 1200 rpm at 4 ° C for 3 minutes, pipetted, and the cells were dispensed into a cell culture dish together with the culture medium, and the culture medium was changed every 3 days. Cells used for seeding were Passage 2 cells at 1 × 10 5 cells / scaffold per support.

(2) 물성 및 효능 분석(2) Analysis of physical properties and efficacy

(2-1) 세포의 증식률 평가(2-1) Evaluation of cell proliferation rate

하이드로겔 지지체에서 세포의 증식률을 알아보고자 MTT (디메틸치아졸-2-일-2,5-디페닐테트라졸리움 브로마이드) 분석법을 시행한 결과, 시간이 증가할수록 세포증식률이 모든 군에서 증가하는 것을 확인하였다. 또한, 모든 타임 포인트에서 1 mg H/G에서 가장 우수한 세포증식률을 보였다.As a result of MTT (dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay, the cell proliferation rate was increased in all groups with increasing time Respectively. In addition, it showed the best cell growth rate at 1 mg H / G at all time points.

그 결과는 도 2에 나타내었는바. 여기서 헤스페리딘/젤란검 하이드로겔 지지체에 파종된 토끼 연골세포의 증식률을 확인할 수 있다.The results are shown in Fig. Here, the proliferation rate of rabbit chondrocytes sown on the hesperidin / gellan gum hydrogel support can be confirmed.

(2-2) 세포의 모폴로지 확인(2-2) Confirmation of cell morphology

제작된 하이드로겔 지지체를 동결건조 시킨 후 SEM을 이용해 지지체 표면 다공을 관찰하였다. 토끼 무릎 연골세포를 채취한 후 지지체에서 2주간 배양하고 2.5 % 글루타 알데하이드를 이용해 고정한 후, 연골세포의 모폴로지를 확인하였다. The prepared hydrogel supports were lyophilized and the surface porosity of the support was observed by SEM. After rabbit knee cartilage cells were harvested, they were cultured on a scaffold for 2 weeks, fixed with 2.5% glutaraldehyde, and the morphology of chondrocytes was confirmed.

도 3은 상기 제조된 헤스페리딘/젤란검 하이드로겔 지지체 위에 파종된 토끼 연골세포를 파종 후 2주 뒤에 BIo-LV SEM을 통해 확인한 사진이다. 여기서는 1 mg 헤스페리딘이 함유된 젤란검 하이드로겔에서 세포의 증식이 가장 많이 일어난 것을 확인할 수 있었으며, 세포외 기질 또한 형성이 많이 되었다. FIG. 3 is a photograph of the rabbit chondrocytes sown on the prepared hesperidin / gellan gum hydrogel support through BIo-LV SEM 2 weeks after sowing. In this case, the cell proliferation was the most prominent in gellan gum hydrogel containing 1 mg hesperidin, and extracellular matrix was also formed.

(2-3) 지지체의 압축강도 분석(2-3) Analysis of compressive strength of the support

헤스페리딘/젤란검 지지체의 압축강도를 측정하기 위해 실험실용 프레스(TMS-Pro, Food Technology Corporation, Sterling, USA)를 사용하였다. 이때 측정 속도는 1mm/sec, 측정 힘은 0.5N으로 설정하여, 압축강도를 측정하였다. 지지체 균열파괴시의 하중을 지지체의 단면적으로 나누었다. A laboratory press (TMS-Pro, Food Technology Corporation, Sterling, USA) was used to measure the compressive strength of the hesperidin / gellan gum backing. At this time, the measurement speed was set to 1 mm / sec, and the measurement force was set to 0.5 N to measure the compressive strength. The load at the fracture of the support crack was divided by the cross-sectional area of the support.

도 4는 헤스페리딘/젤란검 하이드로겔 지지체의 압축강도를 측정한 그래프이다. 측정 결과, 0mg 헤스페리딘이 함유된 젤란검 하이드로겔에서 5N 이상의 압축강도가 관찰되었으며, 1, 2 및 4mg 헤스페리딘이 함유된 젤란검 하이드로겔에서는 헤스페리딘 함량이 증가할수록 압축강도가 점차 감소하는 경향성을 나타냈다.4 is a graph showing the compressive strength of a hesperidin / gellan gum hydrogel support. As a result, the compressive strength of gellan gum hydrogel containing 0 mg hesperidin was more than 5 N and the gel strength of gelatin gel hydrogel containing 1, 2 and 4 mg hesperidin was decreased with increasing hesperidine content.

(2-4) 유전자 발현 분석(2-4) Analysis of gene expression

젤란검 하이드로겔과 헤스페리딘이 배합된 하이드로겔의 유전자 표현형이 비교되었을 때, 헤스페리딘이 함유된 젤란검 하이드로겔에서 발현이 더 잘된 것을 확인하였다.  When the gene phenotypes of the hydrogels containing gellan gum hydrogel and hesperidin were compared, it was confirmed that the expression was better in gellan gum hydrogel containing hesperidin.

도 5a, 도 5b, 도 5c는 상기 결과로서 헤스페리딘/젤란검 하이드로겔 지지체에서 헤스페리딘 함량을 달리한 헤스파리딘 함량별 젤란검 하이드로겔 지지체에 파종된 토끼 연골세포의 연골 관련 마커 유전자 발현도를 항존 유전자(Housekeeping gene) Beta-actin을 사용하여 RT-PCR로 측정한 그래프이다.5a, 5b and 5c show that the expression of the cartilage-related marker gene of rabbit chondrocytes seeded on a gellan gum hydrogel support by the content of hesperidin in the hesperidin / gellan gum hydrogel support, (Housekeeping gene) RT-PCR using Beta-actin.

여기서 어그리칸과 제 I, II형 콜라겐과 같은 ECM-연관 유전자 발현결과에 따르면, 헤스페리딘이 배합된 젤란검 하이드로겔은 바람직한 ECM의 합성을 향상시키는 더 적합한 미세 환경을 제공할 수 있을 것으로 사료된다. Here, ECM-related gene expression results, such as aggrecan and type I and type II collagen, suggest that hesperidin-incorporated gellan gum hydrogels may provide a more suitable microenvironment that enhances the synthesis of the desired ECM .

(2-5) 실험결과(2-5) Experimental results

상기와 같은 실험결과로부터, 본 발명에 따른 헤스페리딘/젤란검 하이드로겔은 기존의 제조 방법보다 간단하고, 겔 형태를 유지할 수 있고, 보관이 용이하다. 또한, 세포의 성장이 완결된 후에는 자연적으로 생분해되어 몸에 흡수되기 때문에 다른 재료보다 생체 적합한 장점이 있는 것으로 확인되었다.From the above experimental results, the hesperidin / gellan gum hydrogel according to the present invention is simpler than the conventional preparation method, can maintain the gel shape, and is easy to store. In addition, after cell growth is completed, it is naturally biodegraded and absorbed into the body.

또한, 실시예의 경우 헤스페리딘을 사용하지 않은 비교예에 비해 현저하게 각종 물성 및 세포의 성장 효과가 우수하여 연골 손상 치료에 효과가 있는 것으로 확인되었다.In addition, in the case of the example, it was confirmed that it is remarkably effective in the treatment of cartilage damage due to its excellent various properties and growth effect of cells compared to the comparative example in which hesperidin was not used.

Claims (8)

연골 재생 및 골염증을 완화 유효성분으로 헤스페리딘이 젤란검에 배합되어 하이드로겔 형태로 이루어진 것을 특징으로 하는 헤스페리딘이 함유된 젤란검 하이드로겔 조성물.
Wherein the hesperidin is combined with gellan gum in the form of a hydrogel as an effective ingredient for alleviating cartilage regeneration and bone inflammation.
청구항 1에 있어서, 젤란검 하이드로겔의 농도는 0.5 ~ 1 중량%인 것을 특징으로 하는 헤스페리딘이 함유된 젤란검 하이드로겔 조성물.
The gellan gum hydrogel composition according to claim 1, wherein the concentration of the gellan gum hydrogel is 0.5 to 1 wt%.
청구항 1에 있어서, 헤스페리딘의 농도는 젤란검에 대하여 5 ~ 20중량% 인 것을 특징으로 하는 헤스페리딘이 함유된 젤란검 하이드로겔 조성물.
The hesperidin-containing gellan gum hydrogel composition according to claim 1, wherein the concentration of hesperidin is 5 to 20% by weight based on the gellan gum.
청구항 1 내지 청구항 3 중에서 선택된 어느 하나의 항에 따른 헤스페리딘이 함유된 젤란검 하이드로겔 조성물을 포함하는 연골 손상 치료용 조성물.
A composition for treating cartilage damage comprising a gellan gum hydrogel composition containing hesperidin according to any one of claims 1 to 3.
청구항 4에 있어서, 주사제 형태로 사용되는 것을 특징으로 하는 연골 손상 치료용 조성물.
The composition for treating cartilage damage according to claim 4, which is used in the form of an injection.
청구항 4에 따른 연골 손상 치료용 조성물을 포함하는 주사용 관절염 치료제.
A therapeutic agent for injectable arthritis comprising a composition for treating cartilage damage according to claim 4.
청구항 6에 있어서, 연골손상 부위에 따라 3-5ml 범위로 투여량을 조절할 수 있는 것을 특징으로 하는 주사용 관절염 치료제.
[Claim 7] The therapeutic agent for arthritis according to claim 6, wherein the dosage can be adjusted in the range of 3-5 ml depending on the cartilage damage site.
청구항 7에 있어서, 연골 손상 정도 및 재생 정도에 따라 주 또는 월 단위로, 반복 투여하는 것을 특징으로 하는 주사용 관절염 치료제. [Claim 7] The therapeutic agent for arthritis for injectable use according to claim 7, which is administered repeatedly on a weekly or monthly basis depending on the degree of cartilage damage and degree of regeneration.
KR1020170095823A 2017-07-28 2017-07-28 Gellan-gum hydrogels composition containing hesperidin KR102008232B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020170095823A KR102008232B1 (en) 2017-07-28 2017-07-28 Gellan-gum hydrogels composition containing hesperidin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170095823A KR102008232B1 (en) 2017-07-28 2017-07-28 Gellan-gum hydrogels composition containing hesperidin

Publications (2)

Publication Number Publication Date
KR20190012593A true KR20190012593A (en) 2019-02-11
KR102008232B1 KR102008232B1 (en) 2019-08-07

Family

ID=65369886

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170095823A KR102008232B1 (en) 2017-07-28 2017-07-28 Gellan-gum hydrogels composition containing hesperidin

Country Status (1)

Country Link
KR (1) KR102008232B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200113689A (en) * 2019-03-26 2020-10-07 전북대학교산학협력단 Gellan gum hydrogel composition comprising agar or agarose, method of manufacuring the same and use of the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4838772A (en) 1971-09-17 1973-06-07
JP2005255527A (en) 2004-03-09 2005-09-22 Matsuura Yakugyo Kk Composition for in vivo collagen synthesis promotor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4838772A (en) 1971-09-17 1973-06-07
JP2005255527A (en) 2004-03-09 2005-09-22 Matsuura Yakugyo Kk Composition for in vivo collagen synthesis promotor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
1. Balakrishnan B1, Joshi N1, Jayakrishnan A2, Banerjee R3, Self-crosslinked oxidized alginate/gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration, Acta Biomater, 2014 Aug;10(8):3650-63.
Austin Arthritis 1(2):1-9(2016.)* *
Tissue Engineering 16(1):343-354(2010.)* *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200113689A (en) * 2019-03-26 2020-10-07 전북대학교산학협력단 Gellan gum hydrogel composition comprising agar or agarose, method of manufacuring the same and use of the same

Also Published As

Publication number Publication date
KR102008232B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
Aramwit Introduction to biomaterials for wound healing
EP3067069B1 (en) Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
JP3634844B2 (en) Stimulation of cartilage growth by agonists of non-proteolytically activated thrombin receptors
Chicatun et al. Collagen/chitosan composite scaffolds for bone and cartilage tissue engineering
Yan et al. Controlled release of BMP-2 from a heparin-conjugated strontium-substituted nanohydroxyapatite/silk fibroin scaffold for bone regeneration
Talaat et al. Nanoscale thermosensitive hydrogel scaffolds promote the chondrogenic differentiation of dental pulp stem and progenitor cells: a minimally invasive approach for cartilage regeneration
WO2009101518A2 (en) Gellan gum based hydrogels for regenerative medicine and tissue engineering applications, its system, and processing devices
WO2022116359A1 (en) Hydrogel loaded with bone morphogenetic protein, and preparation method and application
KR101902194B1 (en) Injectable Curcumin/Gellan Gum Hydrogels for Cartilage Regeneration
Wang et al. Advances in mechanical properties of hydrogels for cartilage tissue defect repair
KR102631542B1 (en) Dual function peptide of anti-inflammation and chondrogenic differentiation of stem cells and use of the same
Xu et al. A bioinspired and high-strengthed hydrogel for regeneration of perforated temporomandibular joint disc: Construction and pleiotropic immunomodulatory effects
KR102008232B1 (en) Gellan-gum hydrogels composition containing hesperidin
WO2020225336A1 (en) Novel polysaccharide-based hydrogel scaffolds for wound care
AU2002239965B2 (en) Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
KR102517764B1 (en) Composition for preventing or treating of articular and cartilage injuries containing hyaluronic acid and pluronic
KR102048914B1 (en) Gellan-gum Hydrogels Composition containing Chondroitin Sulfate
KR102222782B1 (en) Gellan gum hydrogel composition comprising agar or agarose, method of manufacuring the same and use of the same
Tsuda et al. Ultraviolet light‐irradiated photocrosslinkable chitosan hydrogel to prevent bone formation in both rat skull and fibula bone defects
Bhatt et al. Biopolymers in medical implants
WO2019114029A1 (en) Biomimetic chitosan filler for preventing capsular contracture and preparation method therefor
KR20190050416A (en) Composition for Gellan-gum Hydrogels Containing miRNA-140-5p and Composition for treatment of Cartilage Regeneration using it
KR20200043095A (en) Gellan gum hydrogel composition comprising demineralized bone powder of Ogolyge and use of the same
EP2388023A1 (en) Composites on a basis of bioceramics and biodegradable or non biodegradable polymers, containing antibiotics for tissue restitution and products therefrom
Yuan et al. Meniscal Regenerative Scaffolds Based on Biopolymers and Polymers: Recent Status and Applications

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant